What is EVOTEC?
Evotec is a global platform company dedicated to discovering and developing highly effective therapeutics for patients worldwide. Leveraging a data-driven, multimodality platform, Evotec combines innovative technologies for the creation of first-in-class and best-in-class pharmaceutical products. The company's mission is to accelerate the journey from discovery to development, making crucial treatments accessible to those in need. Its strategic focus on both proprietary research and partnerships positions it as a key enabler in the pharmaceutical innovation ecosystem.
How much funding has EVOTEC raised?
EVOTEC has raised a total of $772.9M across 8 funding rounds:
Stock Offering
$69.4M
Share Placement
$32.5M
Share Placement
$96.1M
Debt
$89.8M
Grant
$23.8M
Private Equity
$292.4M
Grant
$8.5M
Debt
$160.4M
Stock Issuance/Offering (1999): $69.4M, investors not publicly disclosed
Share Placement (2013): $32.5M led by Biotechnology Value Fund
Share Placement (2017): $96.1M supported by Novo A/S
Debt (2017): $89.8M featuring European Investment Bank
Grant (2019): $23.8M backed by Bill & Melinda Gates Foundation
Private Equity (2020): $292.4M with participation from Mubadala and Novo Holdings
Grant (2022): $8.5M led by German Federal Ministry of Education and Research
Debt (2023): $160.4M supported by European Investment Bank
Key Investors in EVOTEC
Novo A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on investments within the life sciences sector.
European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution, supporting key EU policy objectives.
Mubadala
Mubadala is a global investment company based in Abu Dhabi, United Arab Emirates, with a mandate to create sustainable financial returns and foster a diversified economy.
What's next for EVOTEC?
With its substantial enterprise-level backing and recent strategic investment, EVOTEC is poised for accelerated expansion and innovation. The company's established platform and commitment to therapeutic development suggest a trajectory focused on advancing its pipeline and potentially forging new strategic alliances. Future endeavors will likely involve scaling operations, enhancing its technological capabilities, and continuing its mission to bring life-changing treatments to market, solidifying its position as a leader in pharmaceutical discovery and development.
See full EVOTEC company page
